What is Wedbush’s Estimate for ANRO FY2029 Earnings?

Alto Neuroscience, Inc. (NYSE:ANRO) – Wedbush issued their FY2029 earnings per share (EPS) estimates for Alto Neuroscience in a research note issued to investors on Thursday, March 20th. Wedbush analyst L. Chico forecasts that the company will post earnings of ($2.88) per share for the year. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share.

Separately, William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a research note on Friday. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Alto Neuroscience presently has a consensus rating of “Moderate Buy” and an average price target of $16.75.

Alto Neuroscience Trading Down 0.2 %

NYSE ANRO opened at $2.65 on Monday. The business has a 50 day moving average price of $3.60 and a 200-day moving average price of $5.98. Alto Neuroscience has a 52 week low of $2.58 and a 52 week high of $18.35. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. The company has a market cap of $71.34 million and a price-to-earnings ratio of -1.04.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.09.

Institutional Trading of Alto Neuroscience

Several institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC grew its position in Alto Neuroscience by 148.7% during the third quarter. Geode Capital Management LLC now owns 469,988 shares of the company’s stock valued at $5,378,000 after buying an additional 281,018 shares during the period. State Street Corp lifted its stake in Alto Neuroscience by 123.7% in the third quarter. State Street Corp now owns 236,857 shares of the company’s stock valued at $2,710,000 after purchasing an additional 130,985 shares during the last quarter. Franklin Resources Inc. raised its stake in shares of Alto Neuroscience by 95.3% in the third quarter. Franklin Resources Inc. now owns 1,220,712 shares of the company’s stock valued at $13,965,000 after buying an additional 595,673 shares during the period. Jane Street Group LLC purchased a new position in shares of Alto Neuroscience during the 3rd quarter valued at $124,000. Finally, Barclays PLC grew its stake in shares of Alto Neuroscience by 872.7% during the 3rd quarter. Barclays PLC now owns 29,599 shares of the company’s stock worth $339,000 after acquiring an additional 26,556 shares during the period.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.